GLANDNSEQ1FY23July 20, 2022

Gland Pharma Limited

1,799words
1turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs 25
July 20, 2022 BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245 Dear Sir/Madam, National Stock Exchange
41%
rations (INR Mn) 11,539 8,569 11,030 8,569 EBITDA (1) / EBITDA Margin (2) (INR Mn / %) 4,981 41% 3,443 37% 4,136 35% 3,443 37% Q1 FY22 Q1 FY23 Q4 FY22 Q1 FY23 Q1 FY22 Q1 FY23 Q4 FY22
37%
Mn) 11,539 8,569 11,030 8,569 EBITDA (1) / EBITDA Margin (2) (INR Mn / %) 4,981 41% 3,443 37% 4,136 35% 3,443 37% Q1 FY22 Q1 FY23 Q4 FY22 Q1 FY23 Q1 FY22 Q1 FY23 Q4 FY22 Q1 FY23 PB
35%
8,569 11,030 8,569 EBITDA (1) / EBITDA Margin (2) (INR Mn / %) 4,981 41% 3,443 37% 4,136 35% 3,443 37% Q1 FY22 Q1 FY23 Q4 FY22 Q1 FY23 Q1 FY22 Q1 FY23 Q4 FY22 Q1 FY23 PBT / PAT / PA
29%
Q1 FY23 Q1 FY22 Q1 FY23 Q4 FY22 Q1 FY23 PBT / PAT / PAT Margin (3) (INR Mn / %) 4,718 3,507 29% 29% 3,085 2,292 25% 28% R&D Expenses / (R&D % of Revenue) (INR Mn / %) 3,805 2,859 3,085
25%
3 Q4 FY22 Q1 FY23 PBT / PAT / PAT Margin (3) (INR Mn / %) 4,718 3,507 29% 29% 3,085 2,292 25% 28% R&D Expenses / (R&D % of Revenue) (INR Mn / %) 3,805 2,859 3,085 2,292 25% 24% 3.8% 0
28%
FY22 Q1 FY23 PBT / PAT / PAT Margin (3) (INR Mn / %) 4,718 3,507 29% 29% 3,085 2,292 25% 28% R&D Expenses / (R&D % of Revenue) (INR Mn / %) 3,805 2,859 3,085 2,292 25% 24% 3.8% 0.1%
24%
2,292 25% 28% R&D Expenses / (R&D % of Revenue) (INR Mn / %) 3,805 2,859 3,085 2,292 25% 24% 3.8% 0.1% 438 7 431 3.7% 4.8% 0.7% 410 61 349 4.1% 5.1% 1.1% 559 116 4.8% 410 0.7%
3.8%
92 25% 28% R&D Expenses / (R&D % of Revenue) (INR Mn / %) 3,805 2,859 3,085 2,292 25% 24% 3.8% 0.1% 438 7 431 3.7% 4.8% 0.7% 410 61 349 4.1% 5.1% 1.1% 559 116 4.8% 410 0.7% 61
0.1%
% 28% R&D Expenses / (R&D % of Revenue) (INR Mn / %) 3,805 2,859 3,085 2,292 25% 24% 3.8% 0.1% 438 7 431 3.7% 4.8% 0.7% 410 61 349 4.1% 5.1% 1.1% 559 116 4.8% 410 0.7% 61 4.0%
3.7%
es / (R&D % of Revenue) (INR Mn / %) 3,805 2,859 3,085 2,292 25% 24% 3.8% 0.1% 438 7 431 3.7% 4.8% 0.7% 410 61 349 4.1% 5.1% 1.1% 559 116 4.8% 410 0.7% 61 4.0% 443 4.1% 349 Q1
4.8%
R&D % of Revenue) (INR Mn / %) 3,805 2,859 3,085 2,292 25% 24% 3.8% 0.1% 438 7 431 3.7% 4.8% 0.7% 410 61 349 4.1% 5.1% 1.1% 559 116 4.8% 410 0.7% 61 4.0% 443 4.1% 349 Q1 FY22
Speaking time
Corporate Office
1
Advertisement
Opening remarks
Corporate Office
Gland Pharma Limited Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India 543245 GLAND GLAND:IN 11
Advertisement
← All transcriptsGLAND stock page →